Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Alexion is another strong buy, with eight "buy" ratings and one "hold." View which stocks are hot on social media with MarketBeat's trending stocks report. Comparatively, 31.1% of Seagen shares are held by insiders. Simply put, patients with PNH lack a type of protein that protects their red blood cells from being targeted by their own immune systems. View Alexion Pharmaceuticals, Inc. ALXN investment & stock information. View our full suite of financial calendars and market data tables, all for free. This treatment, which is provided once every two weeks via intravenous injection, targets a rare blood disorder known as paroxysmal nocturnal hemoglobinuria (PNH). Alexion Pharmaceuticals has a consensus price target of $155.6818, indicating a potential upside of 2.70%. Regeneron Pharmaceuticals beats Alexion Pharmaceuticals on 9 of the 14 factors compared between the two stocks. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Alexion Pharmaceuticals. To see all exchange delays and terms of use please see disclaimer. Currency in USD. Given Amgen's stronger consensus rating and higher possible upside, equities analysts clearly believe Amgen is more favorable than Alexion Pharmaceuticals. Copyright © 2021 MarketWatch, Inc. All rights reserved. Fundamental company data provided by Zacks Investment Research. 83.5% of Biogen shares are owned by institutional investors. Alexion Pharmaceuticals, Inc. operates as a biopharmaceutical company. Given Biogen's higher possible upside, equities research analysts plainly believe Biogen is more favorable than Alexion Pharmaceuticals. Stock Alert: Alexion Pharma Up 7% . (RTTNews) - British drug major AstraZeneca Plc. Seagen beats Alexion Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. In December 2011, Alexion acquired Montreal-based Enobia Pharma Corp, the developer of asfotase alfa, a drug used to treat the genetic disorder hypophosphatasia. Start Your Risk-Free Trial Subscription Here, Editor of top German newspaper suspended in compliance probe, Timing key in consulting deal between FirstEnergy, regulator, You Must Recognize Your Own Achievements First Before Expecting Others To, The Latest: Paris may face new lockdown as ICUs fill up, 'Big burden' for schools trying to give kids internet access, The Latest: Pakistan imposes partial lockdown in some areas, Three Mall Retailers For Your Reopening Watchlist, 3 Growth Stocks with Above Market Dividend Yields, 3 Best Stocks to Buy That You’ve Probably Never Heard Of, Ferroglobe Will Get a Big Lift From Demand For Silcon Wafers, Blue Bird Stock is a Dual Tailwinds EV and Re-Opening Play, Nautilus Stock is a Pullback Buying Opportunity Here, The Launch of Truforma Should Send Zomedica to An All-Time High, Defi Markets Pause But New Highs Are In Sight, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, Receive Analysts' Upgrades and Downgrades Daily. Alexion Pharmaceuticals beats Gilead Sciences on 8 of the 15 factors compared between the two stocks. This table compares Amgen and Alexion Pharmaceuticals' revenue, earnings per share (EPS) and valuation. This is a breakdown of current ratings and target prices for Biogen and Alexion Pharmaceuticals, as reported by MarketBeat.com. The relative strength of a dividend stock indicates whether the stock is uptrending or not. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by insiders. This table compares Alexion Pharmaceuticals and Vertex Pharmaceuticals' revenue, earnings per share (EPS) and valuation. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by insiders. (RTTNews) - British drug major AstraZeneca Plc. Our Accessibility Statement Alexion Pharmaceuticals currently has a consensus target price of $155.6818, suggesting a potential upside of 2.70%. Seagen is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Gilead Sciences has higher revenue and earnings than Alexion Pharmaceuticals. ALXN, Alexion Pharmaceuticals - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Alexion's annual revenue, after all, could more than double from current levels by 2025. Amgen beats Alexion Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get short term trading ideas from the MarketBeat Idea Engine. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. The major determining factor in this rating is whether the stock is trading close to its 52-week-high. Why Is Alexion (ALXN) Down 3.5% Since Last Earnings Report? MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. (AZN.L, AZN) agreed to buy Alexion Pharmaceuticals Inc. (ALXN) for $175 per share in cash and stock, valuing the … 0.1% of Gilead Sciences shares are owned by company insiders. 24 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations. This table compares Biogen and Alexion Pharmaceuticals' net margins, return on equity and return on assets. It’s an Opportunity for Investors. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Amgen has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola’s common stock at a price of $18 per share in cash. Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Alexion Pharmaceuticals, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Seagen (SGEN). Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Prices shown are actual historical values and are not adjusted for either splits or dividends. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Alexion Pharmaceuticals has lower revenue, but higher earnings than Regeneron Pharmaceuticals. Learn more. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Alexion Pharmaceuticals. Gilead Sciences (NASDAQ:GILD) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the better investment? Alexion is collaborating with Zealand Pharma A/S to discover and develop novel peptide therapies for up to four targets in the complement pathway. Summary. This is a breakdown of current ratings and recommmendations for Regeneron Pharmaceuticals and Alexion Pharmaceuticals, as provided by MarketBeat.com. 28, 2020, 09:58 AM (RTTNews) - Shares of Alexion Pharmaceuticals Inc (ALXN) are rising … © American Consumer News, LLC dba MarketBeat® 2010-2021. Alexion stock has been a laggard in the pharma space, largely moving sideways in recent years, despite posting strong growth (sales grew at an average of 17% each year over the last 5 years). We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership. Vertex Pharmaceuticals beats Alexion Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Alexion Pharmaceuticals Inc. for $39 billion in cash and shares, adding a specialist in the treatment of rare diseases and immunology to its portfolio of medications for cancer and other illnesses. Privacy Notice, and Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. Do Not Sell My Information. Regeneron Pharmaceuticals presently has a consensus price target of $629.24, indicating a potential upside of 33.47%. This is a breakdown of current ratings for Alexion Pharmaceuticals and Seagen, as provided by MarketBeat. Alexion Pharmaceuticals beats Gilead Sciences on 8 of the 15 factors compared between the two stocks. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Amgen is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations. Historical and current end-of-day data provided by FACTSET. Biogen beats Alexion Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Find real-time ALXN - Alexion Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. This browser is no longer supported at MarketWatch. Alexion Pharmaceuticals has higher revenue and earnings than Seagen. The end result i… 76.4% of Gilead Sciences shares are owned by institutional investors. We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations. Gilead Sciences is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Stock split history for Alexion Pharmaceuticals since 1996. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Get Alexion Pharmaceuticals Inc (ALXN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Gilead Sciences has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Alexion Pharmaceuticals has higher revenue and earnings than Vertex Pharmaceuticals. The stock's $129 share price and $165 average price target give it a 27% upside. Alexion Pharmaceuticals, Inc. (ALXN) Add to watchlist. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Amgen has higher revenue and earnings than Alexion Pharmaceuticals. A high-level overview of Alexion Pharmaceuticals, Inc. (ALXN) stock. Alexion Pharmaceuticals Inc. stock rises Friday, still underperforms market, Alexion Pharmaceuticals Inc. stock falls Thursday, underperforms market, Alexion Pharmaceuticals Inc. stock rises Wednesday, still underperforms market, Alexion Pharmaceuticals Inc. stock outperforms market on strong trading day, Alexion Pharmaceuticals Inc. stock outperforms market despite losses on the day. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Alexion Pharmaceuticals (NASDAQ:ALXN) and Seagen (NASDAQ:SGEN) are both large-cap medical companies, but which is the better stock? Visit a quote page and your recently viewed tickers will be displayed here. Given Gilead Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Gilead Sciences is more favorable than Alexion Pharmaceuticals. ‘No peace’ for markets until 10-year Treasury yield hits 2%, strategist says, Wisconsin Republican Ron Johnson’s remark about feeling safe in Senate during Capitol riot labeled racist, Marco Rubio links his support for unionizing Amazon workers with an accusation of ‘wokeness’ at company, Vaccine-site volunteers frequently rewarded with early shots, What Bond Investors Should Watch This Week: Fed Decision Edition, Nancy Pelosi’s Husband Bought Up This Investment Firm’s Stock. Want to see which stocks are moving? Export data to Excel for your own analysis. Biogen (NASDAQ:BIIB) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the better investment? 0.4% of Amgen shares are held by insiders. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. This table compares Alexion Pharmaceuticals and Vertex Pharmaceuticals' net margins, return on equity and return on assets. Alexion Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. May. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. The firm focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Create a list of the investments you want to track. The Alexion Pharmaceuticals stock price gained 0.0924% on the last trading day (Friday, 12th Mar 2021), rising from $151.45 to $151.59.During the day the stock fluctuated 1.28% from a day low at $149.87 to a day high … Alexion Stock Jumps on Signal That Fight Over Patent May End Soon. How Will Biotech ETFs React to These Q4 Earnings Releases? 75.2% of Amgen shares are held by institutional investors. This table compares Alexion Pharmaceuticals and Seagen's top-line revenue, earnings per share and valuation. Biogen currently has a consensus price target of $304.4667, indicating a potential upside of 14.41%. Looking for new stock ideas? Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. NasdaqGS - NasdaqGS Real Time Price. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. 4.0% of Alexion Pharmaceuticals shares are held by insiders. This table compares Regeneron Pharmaceuticals and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation. Log in to see them here or sign up to get started. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA. Alexion Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors, Alexion Pharmaceuticals Inc. stock falls Tuesday, underperforms market, Alexion Pharmaceuticals Inc. stock falls Monday, underperforms market, AstraZeneca Sold Its Stake in Rival Covid-19 Vaccine Maker Moderna for More Than $1 Billion, Alexion Pharmaceuticals Inc. stock outperforms competitors despite losses on the day, Alexion Pharmaceuticals Inc. stock underperforms Monday when compared to competitors, Alexion Pharmaceuticals Inc. stock rises Thursday, outperforms market, Alexion Pharmaceuticals Inc. stock rises Wednesday, outperforms market, Immunovant (IMVT) Gains on a Potential Buyout by Roivant. Apellis' (APLS) Q4 Earnings Rise Y/Y, Pegcetacoplan in Focus, Nasdaq ETF's Worst Day Since October: Stocks That Survived, John Paulson's Top 5 Buys of the 4th Quarter, BioNano Genomics’ Next Double Won’t Come Easily, Zacks.com featured highlights include: Sanmina Corp, Canadian Solar, Celestica and Alexion Pharmaceuticals, Alkermes' (ALKS) Q4 Earnings and Revenues Beat Estimates, Prothena's (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat, Ultragenyx (RARE) Q4 Loss Narrows Y/Y, Revenues Beat Estimates, Pick These 4 Low P/CF Stocks for a Value-Based Portfolio, Gilead (GILD) & Galapagos Discontinue Development of IPF Drug. 85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. All quotes are in local exchange time. Gilead Sciences presently has a consensus price target of $96.0370, suggesting a potential upside of 56.01%. There are currently 16 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. 0.5% of Biogen shares are owned by company insiders. Stock analysis for Alexion Pharmaceuticals Inc (ALXN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Its products include ultomiris, soliris, strensiq and kanuma. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. This is a breakdown of current ratings and recommmendations for Amgen and Alexion Pharmaceuticals, as reported by MarketBeat. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. The Investor Relations website contains information about Alexion Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. I want to retire in a college town with warm weather and lower taxes — where should I go? ALXN vs. BMRN: Which Stock Is the Better Value Option? Learn everything you need to know about successful options trading with this three-part video course. You can opt out at any time. Alexion Pharmaceuticals, Inc. Common Stock (ALXN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. This table compares Gilead Sciences and Alexion Pharmaceuticals' gross revenue, earnings per share and valuation. Alexion Pharmaceuticals has a consensus target price of $155.6818, indicating a potential upside of 2.70%. This table compares Biogen and Alexion Pharmaceuticals' gross revenue, earnings per share and valuation. This is a breakdown of current recommendations and price targets for Alexion Pharmaceuticals and Vertex Pharmaceuticals, as provided by MarketBeat. (AZN.L, AZN) agreed to buy Alexion Pharmaceuticals Inc. (ALXN) for $175 per share in cash and stock, valuing the … Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. View real-time stock prices and stock quotes for a full financial overview. Therefore, bargain hunters might want to take advantage of this weakness in the pharma … Comparatively, 87.2% of Seagen shares are held by institutional investors. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. How has Alexion Pharmaceuticals's share price performed over time and what events caused price changes? Amgen currently has a consensus target price of $257.2174, indicating a potential upside of 11.66%. Biogen has higher revenue and earnings than Alexion Pharmaceuticals. Please log in to your account or sign up in order to add this asset to your watchlist. By using this site you agree to the 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. This table compares Regeneron Pharmaceuticals and Alexion Pharmaceuticals' net margins, return on equity and return on assets. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. While Alexion has four revenue-generating products, 70% of the company's sales have come from one drug, Soliris. Learn about financial terms, types of investments, trading strategies and more. Subscriber Agreement & Terms of Use, Cookie Notice (). Get daily stock ideas top-performing Wall Street analysts. Latest Share Price and Events Stable Share Price : ALXN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week. In May 2015, Alexion announced plans to purchase the Lexington firm Synageva BioPharma, a maker of rare disease treatments, in an $8.4 billion stock-and-cash deal. Regeneron Pharmaceuticals (NASDAQ:REGN) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the better stock? Alexion Pharmaceuticals stock price ended on $151.59 on Friday after gaining 0.0924% (Updated on March 12, 2021) Sell candidate since 2021-03-02 Gain 0.81% PDF . Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. Should you be buying ALXN stock or one of its competitors? ALXN | Complete Alexion Pharmaceuticals Inc. stock news by MarketWatch. Alexion Pharmaceuticals (NASDAQ:ALXN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, risk and valuation. This table compares Amgen and Alexion Pharmaceuticals' net margins, return on equity and return on assets. For the best MarketWatch.com experience, please update to a modern browser. This table compares Alexion Pharmaceuticals and Seagen's net margins, return on equity and return on assets. Amgen (NASDAQ:AMGN) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership. Please see … Gilead Sciences has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Have Watchlists? Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. See what's happening in the market right now with MarketBeat's real-time news feed. Learn more. Alexion Pharmaceuticals has a consensus price target of $155.6818, indicating a potential upside of 2.70%. Alexion Pharmaceuticals presently has a consensus target price of $155.6818, indicating a potential upside of 2.70%. Alexion Pharmaceuticals has a consensus price target of $155.6818, suggesting a potential upside of 2.70%. Vertex Pharmaceuticals has a consensus target price of $293.1250, suggesting a potential upside of 36.76%. This is a breakdown of current ratings and price targets for Gilead Sciences and Alexion Pharmaceuticals, as reported by MarketBeat.com. Alexion Pharmaceuticals topped Wall Street's fourth-quarter expectations Thursday, but ALXN stock tanked on mixed guidance for 2020.. X. Intraday Data provided by FACTSET and subject to terms of use. Regeneron Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. RTTNews . This table compares Gilead Sciences and Alexion Pharmaceuticals' net margins, return on equity and return on assets. Get the latest Alexion Pharmaceuticals, Inc. ALXN detailed stock quotes, stock data, Real … 4.0% of Alexion Pharmaceuticals shares are held by insiders. Biogen is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Receive a free world-class investing education from MarketBeat. Biogen has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Seagen has a consensus target price of $188.4615, indicating a potential upside of 25.03%. Comparatively, Seagen has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. Leerink Partners Believes Alexion Pharmaceuticals (ALXN) Still Has Room to Grow. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 5 Best PEG-Driven Value Stocks Amid COVID-Led Uncertainty, AstraZeneca (AZN) Q4 Earnings, Sales Top Despite COVID-19 Woes, Top Ranked Growth Stocks to Buy for February 10th. Intraday data delayed at least 15 minutes or per exchange requirements. Something went wrong while loading Watchlist. There are currently no items in this Watchlist. Vertex Stock Fell After a Setback on a New Drug. Identify stocks that meet your criteria using seven unique stock screeners. Given Seagen's stronger consensus rating and higher possible upside, analysts plainly believe Seagen is more favorable than Alexion Pharmaceuticals. All rights reserved. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed.
Sachs Mofa Neu, Auto Verkaufszahlen Weltweit 2018, Semaglutide Cost Uk, Derbystar Brillant Tt Orange, Statista Gender Pay Gap, Rhein-neckar Löwen Youtube,